The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Economic burden of relapse/recurrence in patients with major depressive disorder
Open accessAbstract
Objective: This study was conducted to determine the incremental healthcare resource utilization (HRU) and costs associated with relapse or recurrence (R/R) in patients with major depressive disorder (MDD) treated with antidepressants (AD) in US clinical practice.Methods: In this retrospective cohort study, adult patients with MDD treated with a branded AD were selected from the Truven Health Analytics MarketScan Databases (January 1, 2004–March 31, 2015). Time to first indicator of R/R was described. Characteristics, HRU, and costs were compared between patients with and without R/R. Among patients with R/R, HRU and costs were also compared between the pre- and post-R/R period.Results: From the 22,236 selected patients, 5,541 had ≥ 1 indicator of R/R and 16,695 did not. The 3-year R/R rate varied between 21.3% and 36.4% based on pattern of AD use (continuous, switch/augmentation, or early discontinuation). Patients with and without R/R presented different characteristics—notably, more intensive prior AD use and a higher comorbidity burden. HRU and costs were high in both patients with and without R/R but substantially higher among those with R/R ($20,590 vs $12,368 per-patient-per-year (PPPY); adjusted difference [aDiff] = $7,037), mainly driven by increased inpatient (IP) services (adjusted incidence rate ratio IP days = 3.95; aDiff IP costs = $3,433 PPPY). Among patients with R/R, emergency department visits, IP days, and IP admissions were over 2-times higher during the post-R/R period and total costs increased by over 50% from $19,267 to $29,419 in the post-R/R period.Conclusions: The economic burden in MDD patients is substantial, but is significantly higher among those who experience R/R.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Patients with a history of relapse have a more complex MDD profile (2)”
From Administrative criteria in the relapse of depressive disorder: a critical appraisal (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Regarding the administrative criteria that have been established, the one mentioned in the largest number of articles is hospitalization, being mentioned in 42 of the 51 (82,3%) articles included in the review (1, 2, 4–7, 9–17, 19–21, 23–31, 34, 35, 41–45, 47–52, 54, 55).”
From Administrative criteria in the relapse of depressive disorder: a critical appraisal (2026) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
Quan, H., Li, B., Couris, C. M., Fushimi, K., Graham, P., Hider, P., Januel, J.-M., & Sundararajan, V. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq433 · Cited by 5,843
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115
The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09298 · Cited by 1,779
Risk for recurrence in depression
Burcusa, S. L., & Iacono, W. G. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.02.005 · Cited by 1,023
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
A Tipping Point for Measurement-Based Care
Fortney, J. C., Unützer, J., Wrenn, G., Pyne, J. M., Smith, G. R., Schoenbaum, M., & Harbin, H. T. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201500439 · Cited by 558
National Institute of Mental Health (NIMH)
(2008) · Encyclopedia of Global Health · doi:10.4135/9781412963855.n834 · Cited by 348
Cognitive and neurological impairment in mood disorders
Marvel, C. L., & Paradiso, S. (2004) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(03)00106-0 · Cited by 256
Research works printed but not linked: 3
- Armstrong C, 2011, Am Fam Physician, 83, 1219
- Thaipisuttikul P, 2014, Neuropsychiatr Dis Treat, 10, 2097
- Sood N, 2000, Am J Manag Care, 6, 1327
Cited by
Chronic mild stress paradigm as a rat model of depression: facts, artifacts, and future perspectives
Strekalova, T. V., Liu, Y., Kiselev, D., Khairuddin, S., Chiu, J. L. Y., Lam, J., Chan, Y., Pavlov, D., Proshin, A. T., Lesch, K., et al. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05982-w · Cited by 158
Forbes, A., Keleher, M. R., Venditto, M., & DiBiasi, F. (2023) · Journal of Medical Internet Research · doi:10.2196/43727 · Cited by 117
Predicting relapse or recurrence of depression: systematic review of prognostic models
Moriarty, A. S., Meader, N., Snell, K. I. E., Riley, R. D., Paton, L. W., Dawson, S., Hendon, J., Chew-Graham, C. A., Gilbody, S., Churchill, R., et al. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.218 · Cited by 71
Ethical Concerns about Psilocybin Intellectual Property
Gerber, K., Flores, I. G., Ruiz, A. C., Ali, I. L., Ginsberg, N. L., & Schenberg, E. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00171 · Cited by 55
Predicting relapse or recurrence of depression: A systematic review of prognostic models
Moriarty, A. S., Meader, N., Snell, K. I. E., Riley, R. D., Paton, L. W., Dawson, S., Hendon, J., Chew-Graham, C. A., Gilbody, S. M., Churchill, R. C., et al. (2022) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 44
Metadata
- Authors
- Gauthier, G., Mucha, L., Shi, S., & Guerin, A.
- Affiliations
- Analysis Group, Inc, Montreal, Canada;
- Takeda (United States) (US)
- ORCID
- Mucha, Lisa
- Venue
- Journal of Drug Assessment
- Publisher
- Informa UK Limited
- Published
- 2019-01-01
- Volume
- 8
- Issue
- 1
- Pages
- 97-103
- ISSN
- 1369-9474 (ISSN-L)
- 2155-6660
- PMC
- PMC6542183
- OpenAlex
- W2942805562
- Cited by
- 36
- References
- 23
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 4 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 2
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Drug Assessment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Takeda Pharmaceutical Center USA
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- major depressive disorder, relapse and recurrence, antidepressants, healthcare resource utilization, health care costs, inpatient services, emergency department visits, antidepressant discontinuation, comorbidities, economic burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic burden of relapse/recurrence in patients with major depressive disorder. https://app.cochat.ai/papers/10.1080/21556660.2019.1612410
- The paper
- Gauthier, G., Mucha, L., Shi, S., & Guerin, A. (2019). Economic burden of relapse/recurrence in patients with major depressive disorder. Journal of Drug Assessment. https://doi.org/10.1080/21556660.2019.1612410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.